Catalyst Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 167
- Market Cap
- $2.4B
- Introduction
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, ...
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy.
- Conditions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Catalyst Pharmaceuticals, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT06564974
- Locations
- 🇺🇸
Arkansas Childrens Hospital, Little Rock, Arkansas, United States
🇺🇸University of Massachusetts Memorial Medical Center, North Worcester, Massachusetts, United States
🇺🇸Duke University Medical Center and Childrens Health Center, Durham, North Carolina, United States
Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
- Conditions
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Catalyst Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT03819660
- Locations
- 🇮🇹
Neurological Institute Carlo Besta, Milano, Lombardy, Italy
Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients
- Conditions
- Interventions
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Catalyst Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT03781479
- Locations
- 🇮🇹
Neurological Institute Carlo Besta, Milano, Lombardy, Italy
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
- Conditions
- Interventions
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Catalyst Pharmaceuticals, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT03579966
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Univerity of Pennsylvania, Philadelphia, Pennsylvania, United States
🇮🇹Department of Neuroimmunology and Neuromuscular Diseases Carlo Besta Neurological Institute Via Celoria, Milan, Italy
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
- Conditions
- Interventions
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Catalyst Pharmaceuticals, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT03304054
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Univerity of Pennsylvania, Philadelphia, Pennsylvania, United States
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
- Conditions
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Catalyst Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT02970162
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Catalyst Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02562066
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Johns Hopkins Pediatric Neurology, Baltimore, Maryland, United States
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Catalyst Pharmaceuticals, Inc.
- Registration Number
- NCT02189720
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
A Safety, Tolerability and Pharmacokinetic Study of CPP-115
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Catalyst Pharmaceuticals, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT01493596
- Locations
- 🇺🇸
Clinilabs, Inc., New York, New York, United States
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
- Conditions
- Interventions
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- Catalyst Pharmaceuticals, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT01377922